Key content
Obstetric cholestasis is also known as intrahepatic cholestasis of pregnancy (ICP).
ICP affects approximately 0.7% of pregnant women in the UK, equating to approximately 6000 women per year.
Pruritus, elevated liver enzymes and raised serum bile acids are key to the diagnosis of ICP.
There is an increased risk of adverse perinatal outcomes associated with severe ICP, including spontaneous preterm birth, meconium staining of the amniotic fluid and stillbirth.
ICP may be treated with ursodeoxycholic acid (UDCA), with some improvement in serum biochemistry and pruritus; however, the impact on the fetus is uncertain.
Learning objectives
To understand the presentation, investigation and management options for women with ICP.
To appreciate the perinatal implications of ICP.
To be aware of the differential diagnoses for antenatal and postnatal abnormal liver function tests.
Ethical issues
Use of unlicensed drugs in pregnancy.
Uncertain feto‐protective benefits of UDCA.
Implications of the adoption of early elective delivery on the development of children born to women with ICP.